NIH-funded research R01 grant

Muscle weakness from high carbon dioxide in COPD

Official title: Metabolic regulation of hypercapnic chronic obstructive pulmonary disease (COPD)-driven skeletal muscle dysfunction

Funded at Albany Medical College · NIH-11235891 · Data updated 2026-11-12

Looks at whether boosting muscle energy production helps people with COPD who retain too much carbon dioxide.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionAlbany Medical College
NIH-funded
Lab location1 site (Albany, United States)
Project startDecember 15, 2021
Project endNovember 30, 2026
Funding year2026
Award (this year)$528,616
NIH project number5R01HL160661-05
Project IDNIH-11235891 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates are people with COPD who retain CO2 (chronic hypercapnia) and who have muscle weakness or trouble with daily activities from fatigue.

Less likely to help

People without CO2 retention or whose muscle problems come from other causes (for example primary neuromuscular diseases) are less likely to benefit.

What this research studies

You will see work focused on why people with COPD who retain CO2 often develop weak, easily tired leg muscles. The team thinks a drop in a key mitochondrial protein (SDHC) reduces ATP and makes muscles more fatigable, and that CO2 alters a signaling pathway (LKB1-AMPK) that controls making new mitochondria. To study this, researchers will use a COPD animal model and lab tests of muscle metabolism and protein levels to trace these changes. The goal is to find biological targets that could be used to prevent or reverse muscle weakness in affected patients.

Why it matters

Potential benefit: If successful, this research could point to treatments that improve muscle strength, reduce fatigue, and possibly improve survival and quality of life for people with CO2-retaining COPD.

How similar studies have gone: Prior research has linked mitochondrial problems to COPD-related muscle weakness, but directly targeting SDHC and the LKB1-AMPK pathway is a newer approach without proven patient treatments yet.

Where this research is happening

  • Albany Medical College
    Albany, United States
    Active

Researchers

  • Principal investigator: Jaitovich, Adolfo Ariel — Albany Medical College
  • Study coordinator: Jaitovich, Adolfo Ariel

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.